Drug Trial Radar · NCT06685809
A Phase 1 Study of FZ008-145 in Healthy Subjects.
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
176
Actual
Start
Nov 25, 2024
Primary completion
Apr 14, 2026
Study completion Apr 14, 2026
Sponsor
- Lead sponsor
- Guangzhou Fermion Technology Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will be conducted in 5 parts: Part A and Part B (single ascending dose \[SAD\] in solution formulation and tablet respectively), Part D and Part D2 (cold pressor test \[CPT\] to evaluate pain tolerance following single dose), and Part E (multiple ascending doses \[MAD\] in tablet formulation).
Conditions
- Healthy
Interventions
FZ008-145 solutionDrug
Dose formulation- Oral solution
FZ008-145 TabletDrug
Dose formulation- Oral tablet
PlaceboDrug
Dose formulation- Matching doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety of FZ008-145 solution by number of adverse events (AEs) and treatment-emergent adverse events (TEAEs)Time frame: up to 14 days post first dose administration
- To assess the safety of FZ008-145 tablet by number of adverse events (AEs) and treatment-emergent adverse events (TEAEs)Time frame: up to 14 days post first dose administration
- Number of participants with changes in laboratory parameters determined as adverse events following oral dose of FZ008-145 solution and FZ008-145 tabletTime frame: up to 14 days post first dose administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research Pty
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.